Clinical trial
Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
NCT00350792 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00350792 |
|---|---|
| Title | Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients |
| Official title | A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, carboplatin |
| Enrollment | 62 |
| Start date | Aug 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2009 |
| First posted | Jul 11, 2006 |
| Last update posted | Oct 13, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: